Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Song, Zhengbo ^a,b   Zhang, Yiping ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology   (China)

Author keywords

Bone metastases; Malignant pleural effusion; Non small cell lung cancer; Survival; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; SURVIVAL TIME; AGED; APOPTOSIS; BONE TUMOR; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLEURAL EFFUSION, MALIGNANT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84894283358     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0898-3     Document Type: Article

References (12)

1. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Ettinger DS, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2008;6:228-69.
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-76.
4. De Marinis F, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280-8.
5. Neville-Webbe HL, et al. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010;37(Suppl 1):S53-65.
6. Gnanta M, et al. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38:407-15.
7. Matsumoto S, et al. Efficacy of the third generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer lines. Lung Cancer. 2005;47:31-9.
8. Berger W, et al. (2005) The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation. Proc Am Assoc Cancer Res 46 (Abst 4981).
9. Noguchi A, et al. Zoledronate-activated V γ 9γδT cell-based immunotherapy is feasible and restores the impairment of γδT cells in patients with solid tumors. Cytotherapy. 2011;13:92-7.
10. Zarogoulidis K, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009;125:1705-9.
11. Stathopoulos GT, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med. 2008;178:50-9.
12. Brown JE, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59-69.